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Female gender has been linked to increased risk of adverse events after surgical aortic valve
replacement; however, the evidence regarding the role of gender differences on clinical out-
comes in patients who underwent transcatheter aortic valve implantation (TAVI) is still
debated. This retrospective study included 910 consecutive patients with severe, symptom-
atic aortic stenosis who underwent TAVI in 2 institutions from January 2012 to July 2016.
The primary end point was all-cause mortality at 1 year after TAVI in women versus men.
Women had a higher incidence of in-hospital vascular complications (7.8% vs 4.1%) and
major or life-threatening bleeding (4.0% vs 1.6%) than men. At 1 year, women showed a
lower mortality rate than men (7.0% vs 12.7%, adjusted hazard ratio [HR] 0.42, 95% con-
fidence interval [CI] [0.23 to 0.76], p = 0.004). When stratifying by specific subgroups of
interest, the survival benefit in women persisted in (1) patients with a Society of Thoracic
Surgery risk score ≤ 8 (adjusted HR 0.35, 95% CI [0.14 to 0.88], p = 0.026); (2) patients
treated with first-generation devices (adjusted HR 0.46, 95% CI [0.24 to 0.86], p = 0.016);
and (3) patients treated with balloon-expandable valves (adjusted HR 0.40, 95% CI [0.19
to 0.86], p = 0.019). In conclusion, in this large patient cohort, women had lower 1-year mor-
tality after TAVI than men, particularly with an STS score ≤ 8, or treated with first-
generation and balloon-expandable devices. © 2018 Elsevier Inc. All rights reserved. (Am
J Cardiol 2018;■■:■■–■■)
Transcatheter aortic valve implantation (TAVI) is the new
standard of care for patients with symptomatic aortic steno-
sis (AS), who are deemed at intermediate or greater risk of
surgical aortic valve replacement (SAVR). Female gender has
been shown to be associated with increased risk of adverse
events after SAVR1–5; however, the evidence regarding the role
of gender differences on clinical outcomes in patients who
underwent TAVI are conflicting.6–11 Some studies suggest that
TAVI is more beneficial in women, yet others report no dif-
ference in outcomes or increased adverse events in women.12–15
A meta-analysis published in 2015 concluded that women have
improved late survival after TAVI.16 This benefit seemed to
occur despite higher periprocedural vascular and bleeding com-
plication rates. The exact reasons for a survival benefit in
women compared with men after TAVI, especially when
women are known to have a higher risk of mortality after
SAVR, have yet to be determined. Moreover, the disparity
in the results of the published studies might be due to patient
selection (inoperable patients vs high-risk patients vs
intermediate-risk patients), generation of the device used (early-
generation devices vs second-generation devices), and type
of device used (balloon-expandable devices vs self-expandable
devices). Given the conflicting data in the literature, we sought
to perform a comprehensive analysis of gender-based differ-
ences in patients having TAVI in our hospital system.
Methods
Data were collected on consecutive patients with severe,
symptomatic AS who underwent TAVI at Baylor Heart and
Vascular Hospital (Dallas, Texas) (n = 348) and The Heart Hos-
pital Baylor Plano (Plano, Texas) (n = 562) from January 2012
to July 2016. Baseline demographics, echocardiographic and
procedural data, discharge therapy, and clinical outcomes were
retrospectively collected and analyzed. For the purpose of the
current analysis, data from both medical centers were pooled,
and a joint database was created. The study was approved by
the Baylor Institutional Review Board. In both centers, patient
screening was based on echocardiographic and computed to-
mography scan images, integrated with laboratory work and
clinical evaluation by the heart team, which is composed of
clinical and interventional cardiologists, heart surgeons, and
experts in cardiac imaging. The following definitions were
used in accordance with the Valve Academic Research
Consortium-2 standardized end point definitions for TAVI con-
sensus document: acute kidney injury; vascular complication;
minor, major, and life-threatening bleedings; stroke; re-
intervention; permanent pacemaker implantation; new-
onset atrial fibrillation; immediate postoperative mortality
(within 72 hours of the procedure); 30-day cardiovascular mor-
tality; and all-cause mortality and 1-year all-cause mortality.17
Cardiovascular mortality at 1 year was not available in all
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patients; therefore, it was not included as an end point. Events
were adjudicated at each center during the regular follow-
up visit. The primary end point of this study was all-cause
mortality at 1 year after TAVI in women versus men. Post-
operative echocardiographic measures were recorded as well
to assess prosthetic valve function. Continuous variables are
summarized as mean ± standard deviation and were com-
pared using Student’s t test or Mann-Whitney rank-sum test.
Categorical variables were compared using chi-square test.
Cox regression was used for multivariate analysis. For the
prediction of 1-year all-cause mortality (dependent vari-
able), baseline variables of clinical interest and/or satisfaction
of the entry criterion of p <0.05 in the univariable analysis
were used as explanatory variables (Society of Thoracic
Surgery [STS] score, gender, coronary artery disease, previ-
ous coronary artery bypass grafting/percutaneous coronary
intervention, body surface area, left ventricle ejection frac-
tion at baseline, stroke volume indexed, and presence of
pacemaker at baseline). Interaction testing was performed to
determine whether the effect of gender was consistent, irre-
spective of STS score and generation and type of device used,
on the primary end point of the study. This test was per-
formed with likelihood ratio tests of the null hypothesis that
the interaction coefficient was zero. Survival curves were con-
structed using Cox regression analysis. A two-sided alpha level
of 0.05 was used for all superiority testing. All statistical analy-
ses were performed using SPSS (version 19) statistical software
(SPSS, Inc., Chicago, Illinois).18
Results
During the study period from January 2012 to July 2016,
a total of 910 patients underwent TAVI, including 423 women
(46.5%) and 487 men (53.5%). Table 1 displays the base-
line characteristics for the study population. Female patients
were somewhat older than male patients, with a smaller body
surface area, a higher STS score, a higher prevalence of hy-
pertension, a lower prevalence of previous percutaneous or
surgical coronary revascularization, a lower prevalence of coro-
nary artery disease, and a lower prevalence of permanent
pacemaker. Women had a higher mean left ventricular ejec-
tion fraction (LVEF) than men, higher aortic valve gradients
but a greater prevalence of moderate or severe aortic valve
regurgitation. Moreover, women had a higher mean gradi-
ent across mitral valve, along with a higher prevalence of mitral
annular calcium.
No differences in the type of device or in the approach
used to deliver the device were observed between women and
men in our population. However, implanted valve sizes were
smaller in women than in men (Table 1).
No significant differences in the use of aspirin, P2Y12 in-
hibitors, and dual antiplatelet therapy were observed across
gender, which is consistent with the standard discharge therapy
after TAVI in our centers. Consistent with a similar preva-
lence of atrial fibrillation in women and men, the use of
anticoagulants alone or in combination with antiplatelet drugs
was not different between genders (Table 1).
Similar to baseline, women had a higher LVEF, higher
aortic valve and mitral valve gradients, and larger left atrial
volume after TAVI (Table 2). LVEF was persistently and sig-
nificantly higher in women than in men during follow-up
(Figure 1). No differences in the incidence of postoperative
aortic and mitral regurgitation were observed between women
and men (Table 2).
Women had a higher incidence of in-hospital vascular com-
plications (7.8% vs 4.1%) and major or life-threatening
bleeding (4.0% vs 1.6%) than men; however, when these
results were adjusted by potential confounders, female gender
was no longer associated with these events (Table 3). Body
surface area, instead of gender, emerged as a significant pre-
dictor of vascular complication (hazard ration [HR] 0.21 for
each 1 unit increase, p = 0.04, data not shown). Nonethe-
less, at 1 year, women showed a lower mortality rate than men
(7.0% vs 12.7%, adjusted HR 0.42, 95% confidence
Figure 1. Left ventricular ejection fraction (LVEF) over time. Trends of LVEF during 1-year follow-up in women and men. TAVR = transcatheter aortic valve
replacement.
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Table 1
Characteristics of the study population
Women (n = 423) Men (n = 487) p
Baseline characteristics
Age (years) 82.0 ± 7.6 80.9 ± 8.4 0.051
Body Mass Index (Kg/m2) 28.7 ± 16.2 27.5 ± 5.8 0.115
Body Surface Area (m2) 1.75 ± 0.22 2.02 ± 0.21 <0.0001
Society of Thoracic Surgery Risk Score (%) 7.9 ± 3.7 7.1 ± 4.0 0.007
Hypertension 367 (88.0%) 401 (82.9%) 0.030
Hyperlipidemia 301 (72.7%) 359 (74.8%) 0.479
Diabetes mellitus 151 (37.7%) 194 (42.0%) 0.195
Chronic kidney disease 188 (45.0%) 229 (47.6%) 0.430
End stage renal disease 10 (2.6%) 16 (3.6%) 0.376
Coronary artery disease 263 (63.1%) 360 (74.7%) <0.0001
Peripheral artery disease 118 (29.4%) 163 (35.3%) 0.067
Chronic obstructive pulmonary disease 85 (21.9%) 98 (21.9%) 0.993
Atrial fibrillation 115 (27.2%) 155 (31.8%) 0.259
Previous coronary bypass/percutaneous coronary intervention 147 (36.8%) 265 (56.9%) <0.0001
Previous cerebrovascular accident 81 (20.7%) 88 (19.8%) 0.749
Permanent pacemaker 69 (16.4%) 103 (21.6%) 0.050
Echocardiographic findings
Left ventricle ejection fraction <40% 56 (13.3%) 96 (20.0%) 0.008
Left ventricle ejection fraction (%) 57.1 ± 12.8 52.3 ± 13.1 <0.0001
Stroke Volume Indexed (ml/beat/m2) 39.5 ± 11.3 36.2 ± 12.3 <0.0001
Aortic valve mean gradient (mmHg) 46.4 ± 14.4 43.2 ± 13.2 0.001
Aortic valve area (cm2) 0.65 ± 0.18 0.71 ± 0.19 <0.0001
Aortic peak velocity (m/sec) 4.4 ± 0.62 4.3 ± 0.62 0.001
Bicuspid aortic valve 44 (10.5%) 61 (12.6%) 0.325
Mitral valve mean gradient (mmHg) 4.0 ± 2.5 2.9 ± 1.8 <0.0001
Mitral annular calcium 394 (93.1%) 407 (83.6%) <0.0001
Aortic regurgitation ≥moderate 54 (12.9%) 41 (8.5%) 0.031
Mitral regurgitation ≥moderate 74 (17.5%) 88 (18.1%) 0.810
Pulmonary Hypertension 240 (74.8%) 269 (75.6%) 0.811
Left atrial volume (ml) 81.8 ± 33.7 85.3 ± 29.3 0.164
Procedural characteristics
Type of Valve 0.448
Balloon-expandable 244 (57.7%) 293 (60.2%)
1st generation 172 (70.5%) 208 (71.0%)
new generation 72 (29.5%) 85 (29.0%)
Self-expandable 179 (42.3%) 194 (39.8%)
1st generation 106 (59.2%) 132 (68.0%)
new generation 73 (40.8%) 62 (32.0%)
Approach 0.539
Trans-femoral 369 (87.2%) 434 (89.1%)
Trans-apical 32 (7.6%) 37 (7.6%)
Trans-aortic 17 (4.0%) 13 (2.0%)
Subclavian 5 (1.2%) 3 (0.6%)
Valve Size (mm)
Balloon-expandable <0.0001
20 12 (5.0%) 0 (0%)
21 1 (0.4%) 0 (0%)
23 148 (61.7%) 25 (8.7%)
26 77 (32.0%) 152 (53.1%)
29 2 (0.8%) 109 (38.1%)
Self-Expandable <0.0001
23 19 (10.7%) 1 (0.5%)
25 6 (3.4%) 6 (3.2%)
26 76 (42.9%) 11 (5.8%)
27 2 (1.1%) 9 (4.7%)
29 70 (39.5%) 91 (47.9%)
31 4 (2.3%) 69 (36.3%)
34 0 (0%) 3 (1.6%)
Discharge Medications
Aspirin 44 (10.4%) 50 (10.3%) 0.947
P2Y12 inhibitor 5 (1.2%) 14 (2.9%) 0.075
Aspirin and P2Y12 inhibitor 274 (64.7%) 294 (60.3%) 0.323
Warfarin 8 (1.9%) 8 (1.6%) 0.776
Factor Xa inhibitor - 1 (0.2%) 0.351
Dabigatran - - -
Aspirin and any anticoagulant 59 (13.9%) 78 (16.0%) 0.384
P2Y12 inhibitor and any anticoagulant 18 (4.3%) 12 (2.5%) 0.131
Triple Therapy 15 (3.5%) 30 (6.2%) 0.070
ARTICLE IN PRESS
3Valvular Heart Disease/Gender Differences and TAVI Outcomes
interval [CI] [0.23 to 0.76], p = 0.004). No differences in any
of the other clinical outcomes analyzed were observed (Table 3,
Figure 2). Interestingly, when the analysis for 1-year all-
cause mortality was stratified by specific subgroups of interest,
the survival benefit of female gender persisted in (1) pa-
tients with an STS score ≤ 8 (low-intermediate) (adjusted HR
0.35, 95% CI [0.14 to 0.88], p = 0.026); (2) patients treated
with first-generation devices (adjusted HR 0.46, 95% CI [0.24
Table 2
Postoperative echocardiographic findings
Variable Women (n = 423) Men (n = 487) p
Left ventricle ejection fraction (%) 57.5 ± 10.9 53.6 ± 12.1 <0.0001
Aortic valve mean gradient (mmHg) 8.9 ± 4.5 8.1 ± 3.9 0.003
Aortic valve area (cm2) 1.8 ± 0.52 2.0 ± 0.60 <0.0001
Aortic peak velocity (m/sec) 2.05 ± 0.52 1.96 ± 0.45 0.087
Mitral valve mean gradient (mmHg) 4.1 ± 2.2 3.2 ± 1.7 <0.0001
Aortic regurgitation ≥moderate 69 (16.3%) 77 (15.8%) 0.837
Mitral regurgitation ≥moderate 25 (11.3%) 35 (12.4%) 0.175
Left atrial volume (ml) 81.6 ± 28.3 101.0 ± 85.8 0.048
Table 3
Clinical outcomes and relative adjusted hazard ratios
Variable Women (n = 423) Men (n = 487) Adjusted HR, 95% [CI] p
In-Hospital Outcomes
Acute Kidney Injury 14 (3.3%) 17 (3.5%) 0.85 [0.24-2.98] 0.913
Vascular complication 33 (7.8%) 20 (4.1%) 1.16 [0.53-2.52] 0.708
Minor bleeding 50 (11.8%) 55 (11.3%) 0.84 [0.47-1.50] 0.553
Major or life-threatening bleeding 17 (4.0%) 8 (1.6%) 2.20 [0.63-1.69] 0.217
Stroke 13 (3.8%) 18 (4.5%) 0.63 [0.20-1.95] 0.421
Valve-in-Valve 4 (1.2%) 12 (3.0%) 0.24 [0.04-1.35] 0.106
Permanent Pacemaker Implantation 72 (17.0%) 95 (19.7%) 0.77 [0.48-1.26] 0.299
New-Onset Atrial Fibrillation 47 (11.1%) 37 (7.6%) 1.48 [0.78-2.82] 0.227
Immediate post-procedural Mortality 4 (0.9%) 3 (0.6%) 0.62 [0.05-1.01] 0.700
30-day Cardiovascular Mortality 7 (1.7%) 13 (2.7%) 0.37 [0.07-1.96] 0.242
30-day All-cause Mortality 12 (2.8%) 14 (2.9%) 0.78 [0.30-2.02] 0.602
1-year All-cause Mortality 24 (7.0%) 51 (12.7%) 0.42 [0.23-0.76] 0.004
Figure 2. Survival curves after TAVR. One-year survival after TAVR in women versus men. HR = hazard ratio; TAVR = transcatheter aortic valve replacement.
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to 0.86], p = 0.016) although with a significant interaction
(p = 0.004); and (3) patients treated with balloon-expandable
valves (adjusted HR 0.40, 95% CI [0.19 to 0.86], p = 0.019)
(Table 4).
Discussion
In this study on 910 consecutive patients, women showed
a significantly lower risk of 1-year all-cause mortality after
TAVI than men. This survival benefit was independently as-
sociated with female gender in 2 specific subgroups of patients:
(1) low- to intermediate-risk patients and (2) patients treated
with balloon-expandable valves.
Previous studies have consistently shown that women have
higher risk of death after SAVR, and gender is included in
the STS risk calculator.1–5 In contrast, our data indicate that
women have a survival advantage after TAVI. Previous studies
on this topic have been conflicting. Data coming from large
registries and meta-analysis also suggested lower mortality
of women after TAVI.16,19–21 In contrast, other studies did not
find any gender-related differences in TAVI outcome.22,23 In
our patients, women experienced a 58% reduction in the risk
of all-cause mortality at 1 year after TAVI, even after adjust-
ing for potential confounders such as coronary artery disease,
previous revascularization, LVEF, body surface area, the pres-
ence of permanent pacemaker at baseline, and stroke volume
index, the latter being a strong predictor of outcomes after
SAVR or TAVI24 (Table 3, Figure 2). It has to be acknowl-
edged, however, that there might be a difference in the
myocardial structural changes between genders because women
are known to undergo greater regression of left ventricular
hypertrophy after aortic valve replacement than men. Men
with AS have been shown to have more cardiac fibrosis and
thus less left ventricular mass regression after aortic valve
replacement.25 However, although left ventricular reverse re-
modeling occurs both after TAVI and after SAVR, women do
not experience better survival after surgery.
Although our findings confirm some previous reports, ours
is the first study to identify subgroups of women with a sur-
vival advantage: lower STS score (meaning that in the high-
risk category, the role of gender is attenuated) and those treated
with balloon-expandable valves (Table 4). In our series, most
patients were treated with balloon-expandable devices, which
could bias the results of this subgroup analysis. All of the pre-
vious studies, however, showed a better survival for women
at 1-year use of balloon-expandable than self-expandable
valves.16,19,20 Data from the Transcatheter Valve Therapy reg-
istry on 23,652 patients reported a better survival in women,
and in this study, more than 88% of patients were treated with
balloon-expandable devices.20,26 O’Connor et al16 published
a patient-level meta-analysis confirming these data, and also
in this case, 2/3 of the population was treated with balloon-
expandable valves. In contrast, 2 studies, by Czarnecki et al22
and Al-Lamee et al23 where balloon-expandable and self-
expandable devices were more balanced, found no differences
in mortality between men and women. In this regard, self-
expandable valves are generally implanted at a lower level
compared with balloon-expandable valves. It has been re-
ported that the lower implantation depth might, in some cases,
interfere with the anterior mitral valve leaflet, leading to mitral
stenosis.27 In our population, women showed higher mitral
gradients at baseline and it is possible that the group treated
with self-expandable valves experience a worsening in mitral
function, which could potentially affect survival in the long
term. In this study, we were not able to specifically address
this hypothesis, which deserves further investigation.
Vascular complications and bleeding have been reported
to be more frequent in women.19,20 In our patients, when the
results were adjusted including potential confounders (men-
tioned previously), it turned out that the event rate was not
different between genders (Table 3). In particular, the only
predictor of vascular complication in our study was body
surface area, with a progressively decreasing risk for each unit
increment in body surface area. Women are generally smaller
in body size than men, and this might have driven the results
of other studies.
This study has several limitations, mainly due to the ret-
rospective design of the study. Since we included TAVI patients
starting in 2012, both old and new generation devices were
used. Moreover, no external committee was used to adjudi-
cate events.
In conclusion, the results of our study demonstrate that
women have a lower mortality after TAVI, particularly with
lower STS risk scores and balloon-expandable valves. Given
that woman have a known higher risk of mortality after SAVR,
these findings may influence clinical decision-making as to
the choice of procedure and implanted valves in women.
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